secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084367
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment
--------------------------------------------------------------------------------

- Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.
- Underwriters exercised in full the 30-day option to purchase an additional 2,647,058 shares on Feb 26, 2026.
- Offering closed on February 27, 2026; net proceeds after discounts and expenses not disclosed.
- Goldman Sachs, Leerink Partners, Evercore, and Barclays acted as representatives of the underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312526084367/0001193125-26-084367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312526084367/d50465d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer